Objective
Lung cancer is the major cause of cancer deaths in Europe, and is claiming more deaths than breast, colon and prostate cancers combined. Early diagnosis allowing surgical resection with a 60 to 80% five years' survival is performed in less than 25% of the patients, stressing the need of identifying molecular biomarkers to improve early detection and therapies. Lung carcinogenesis is a multi-step process characterized by the accumulation of genetic alterations, due to exposure to carcinogens targeting genes controlling cell cycle, DNA repair, apoptosis, senescence, differentiation and cell migration.
ING genes (INhibitor of Growth) are candidate tumour suppressor genes which have been recently identified and characterized by us and others. They encode for proteins associated with cell cycle regulation, apoptosis, senescence and neoplastic transformation. Suppression of ING protein expression can be a critical step of the carcinogenesis process since inactivation of ING1 in preneoplastic cells results in the occurrence of tumours on nude mice (xenografts) and expression of ING1 protein is downregulated in numerous cancer types including breast, blood, esophageal, brain, bladder, stomach and liver cancers.
Our objectives aim at:
1) determining if ING genes may play a role in lung carcinogenesis and be biomarkers predictive of progression of pre-invasive and invasive lesions,
2) validating their interest for use as biomarkers in early diagnosis and/or targeted therapies,
3) understanding the mechanisms of their involvement in lung carcinogenesis.
We will conduct studies on human clinical samples as well as functional studies on cell lines using unique epithelial cells and fibroblast models and combining cell biology, molecular biology and biochemistry techniques. This integrated approach extending from molecular basis of tumour initiation and progression to clinical application in early diagnosis and targeted therapies, aims at decreasing lung cancer death.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- medical and health sciences clinical medicine oncology liver cancer
- medical and health sciences clinical medicine oncology lung cancer
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences biological sciences cell biology
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-MOBILITY-12
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.